As a result of the strong clinical correlation between c-Met expression and metastatic disease, c-Met has been targeted therapeutically to suppress tumor growth and metastasis in lymphoma, gastric cancer, melanoma, and lung cancer [18, 19]. This evidence concerns the gene MET and lung carcinoma.